脂必泰联合阿托伐他汀钙对冠心病患者血脂的影响

摘要

目的:观察脂必泰联合阿托伐他汀钙对冠心病 (CHD) 患者血脂的影响.方法:将120例患者随机分为3组, 每组40例:ZA-10组以脂必泰480 mg+阿托伐他汀钙10 mg治疗;A-20组以阿托伐他汀钙20 mg治疗;A-40组以阿托伐他汀钙40 mg治疗, 3组均治疗8周.测量患者治疗前后总胆固醇 (TC) 、甘油三酯 (TG) 、高密度脂蛋白 (HDL) 、低密度脂蛋白 (LDL) 及载脂蛋白ApoA1、ApoB100、心肌营养因子1 (CT-1) 、高敏C-反应蛋白 (hs-CRP) 、肌酸激酶同工酶 (CK-MB) 水平, 观察不良反应发生情况.结果:治疗后TC、TG、LDL、ApoB100水平3组均显著下降 (P＜0.05) ;TG、LDL、ApoB100水平ZA-10组显著低于A-20、A-40组 (P＜0.05) ;3组患者载脂蛋白ApoA1水平比较无明显差异 (P＞0.05) .血清CT-1和hs-CRP水平3组均显著下降 (P＜0.05) ;CK-MB水平下降不明显 (P＞0.05), hs-CRP水平ZA-10组与A-20、A-40组比较差异显著 (P＜0.05) .不良反应发生率ZA-10组为17.5％, A-20组为25.0％, A-40组为30.0％, ZA-10组与A-40组比较, 差异有统计学意义 (P＜0.05) .结论:脂必泰和阿托伐他汀钙联用可显著降低冠心病患者的TC、TG、LDL、ApoB100、hs-CRP水平, 可减少阿托伐他汀钙的用量, 且不良反应较少.%Objective:To observe the effects of ZhiBiTai and atorvastatin calcium on blood lipid of the patients with coronary heart disease (CHD) . Methods: All 120 patients were randomized into three groups, 40 cases each group:ZA-10 group were treated by ZhiBiTai capsules, 480 mg and atorvastatin calcium, 10 mg; A-20 group were given atorvastatin calcium, 20 mg; A-40 group atorvastatin calcium, 40 mg, three groups were treated for eight weeks. The levels of TC, TG, HDL and LDL ApoA1, ApoB100, cardiotrophin-1 (CT-1), high sensitivity C-reactive protein (hs-CRP) and CK-MB of the patients were detected before and after treating, the incidence of adverse reaction was observed. Results: After treating, the levels of TC, TG, LDL, ApoB100 of three groups lowered notably (P＜0.05) ;ZA-10 group was lower than A-20 and A-40 groups notably in the levels of TG, LDL and ApoB100 (P＜0.05) ; the obvious difference didn't existed in the comparison of the level of ApoA1 among three groups (P＞0.05) . The levels of CT-1 and hs-CRP of three groups decreased remarkably (P＜0.05) ; the level of CK-MB decreased insignificantly (P＞0.05), the difference was significant in the comparison of the levels of hs-CRP when ZA-10 group was compared with A-20 and A-40 groups (P＜0.05) . The incidences of adverse reaction of ZA-10 group, A-20 and A4-group were 17.5％, 25.0％ and 30.0％, the difference had statistical meaning when ZA-10 group was compared with A-40 group (P＜0.05) . Conclusion: The combination of ZhiBiTai capsules and atorvastatin calcium could decrease the levels of TC, TG, LDL, ApoB100 and hs-CRP with minor adverse reaction, and reduce the dose of atorvastatin calcium.